Sinopharm Group Co Ltd (Sinopharm Holding) is in charge of Sinopharm’s medical & pharmaceutical commerce sector. Established in Shanghai in January 2003 and listed on the Hong Kong Stock Exchange in September 2009 (01099.HK), the company has more than 1,100 subsidiaries, including China National Medicines Co Ltd (600511.SH) and China National Accord Medicines Co Ltd (000028.SZ), both of which are listed on the A-share market. It also has a total of approximately 120,000 employees. 

Under the strong leadership of Sinopharm, its parent company, its board of directors and Party committee, Sinopharm Holding deepens its mixed ownership reform, promotes integrated development and implements technological innovation. It has embarked on a development path of organizational restructuring, capital operation, resource integration and integrated innovation, becoming a leading distributor and retailer of pharmaceuticals, health care products and medical equipment, as well as a leading supply chain service provider in China. 

With around 600,000 outlets across the country, Sinopharm Holding’s operating revenue in 2021 reached 521.05 billion yuan ($73.1 billion), a year-on-year increase of 14.16%. The revenue from its pharmaceutical distribution business was 389.95 billion yuan. Its medical equipment business has developed rapidly, with sales revenue reaching 108.13 billion yuan. The network of pharmacies has been optimized and improved, with the total number of pharmacies, including community ones, direct to patient ones and "dual-channel" ones, exceeding 10,000, and their business revenue increased by 20.26% year-on-year. 

Sinopharm Holding thoroughly implements the decisions and deployments made by the Communist Party of China (CPC) Central Committee and the State Council to improve the modernization level and maintain the security and stability of the industrial and supply chain. It has been recognized as a "2022 national demonstration enterprise for supply chain innovation and application" by the Ministry of Commerce and seven other institutes. 

Sinopharm Holding ranked 24th in the 2022 Fortune China 500 and the first among pharmaceutical companies, by virtue of its excellent management and operation. In 2022, Sinopharm Holding's MSCI Environmental, Social, and Governance (ESG) rating was upgraded to A, and it was listed as one of the top 50 companies among listed companies controlled by central enterprises in terms of ESG governance. Ranking 28th in the top 100 most valuable Chinese brands, it takes a leading position in brand value among listed pharmaceutical companies in China.